First, we need to generate human cell lines that will recapitulate phenotypes observed in distinct TSC and LAM lesions, and can potentially give rise to these lesions in vitro and in in vivo mouse models, following controlled induction of TSC1- or TSC2-deficiency. Here, SLC12A3 is linked to lymphangioleiomyomatosis.